Search

Your search keyword '"Hackmann J"' showing total 186 results
Start Over Author "Hackmann J"
186 results on '"Hackmann J"'

1. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Author

Mamounas, E.P., Untch, M., Mano, M.S., Huang, C.-S., Geyer Jr, C.E., von Minckwitz, G., Wolmark, N., Pivot, X., Kuemmel, S., DiGiovanna, M.P., Kaufman, B., Kunz, G., Conlin, A.K., Alcedo, J.C., Kuehn, T., Wapnir, I., Fontana, A., Hackmann, J., Polikoff, J., Saghatchian, M., Brufsky, A., Yang, Y., Zimovjanova, M., Boulet, T., Liu, H., Tesarowski, D., Lam, L.H., Song, C., Smitt, M., and Loibl, S.

Published
2021
Full Text
View/download PDF

2. Spin noise of electrons and holes in (In,Ga)As quantum dots: experiment and theory

Author

Glasenapp, P., Smirnov, D. S., Greilich, A., Hackmann, J., Glazov, M. M., Anders, F. B., and Bayer, M.

Subjects
Condensed Matter - Mesoscale and Nanoscale Physics
Abstract

The spin fluctuations of electron and hole doped self-assembled quantum dot ensembles are measured optically in the low-intensity limit of a probe laser in absence and presence of longitudinal or transverse static magnetic fields. The experimental results are modeled by two complementary approaches based either on semiclassical or quantum mechanical descriptions. This allows us to characterize the hyperfine interaction of electron and hole spins with the surrounding bath of nuclei on time scales covering several orders of magnitude. Our results demonstrate (i) the intrinsic precession of the electron spin fluctuations around the effective nuclear Overhauser field caused by the host lattice nuclear spins, (ii) the comparably long time scales for electron and hole spin decoherence, as well as (iii) the dramatic enhancement of the spin lifetimes induced by a longitudinal magnetic field due to the decoupling of nuclear and charge carrier spins., Comment: 16 pages, 9 figures

Published
2016
Full Text
View/download PDF

3. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., and Untch, M.

Published
2017
Full Text
View/download PDF

4. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Author

von Minckwitz, G., Loibl, S., Untch, M., Eidtmann, H., Rezai, M., Fasching, P.A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Huober, J., Solbach, C., Jackisch, C., Kunz, G., Blohmer, J.U., Hauschild, M., Fehm, T., Nekljudova, V., Gerber, B., Gnauert, K., Heinrich, B., Prätz, T., Groh, U., Tanzer, H., Villena, C., Tulusan, A., Liedtke, B., Blohmer, J.-U., Mau, C., Potenberg, J., Schilling, J., Just, M., Weiss, E., Bückner, U., Wolfgarten, M., Lorenz, R., Doering, G., Feidicker, S., Krabisch, P., Deichert, U., Augustin, D., Kast, K., Nestle-Krämling, C., Höß, C., Terhaag, J., Fasching, P., Staib, P., Aktas, B., Kühn, T., Khandan, F., Möbus, V., Stickeler, E., Heinrich, G., Wagner, H., Abdallah, A., Dewitz, T., Emons, G., Belau, A., Rethwisch, V., Lantzsch, T., Thomssen, C., Mattner, U., Nugent, A., Müller, V., Noesselt, T., Holms, F., Müller, T., Deuker, J.-U., Strumberg, D., Uleer, C., Solomayer, E., Runnebaum, I., Link, H., Tomé, O., Ulmer, H.-U., Conrad, B., Feisel-Schwickardi, G., Schumacher, C., Steinmetz, T., Bauerfeind, I., Kremers, S., Langanke, D., Kullmer, U., Ober, A., Fischer, D., Kohls, A., Weikel, W., Bischoff, J., Freese, K., Schmidt, M., Wiest, W., Sütterlin, M., Dietrich, M., Grießhammer, M., Burgmann, D.-M., Rack, B., Salat, C., Sattler, D., Tio, J., von Abel, E., Christensen, B., Burkamp, U., Köhne, C.-H., Meinerz, W., Graßhoff, S.-T., Decker, T., Overkamp, F., Thalmann, I., Sallmann, A., Beck, T., Reimer, T., Bartzke, G., Deryal, M., Weigel, M., Weder, P., Steffens, C.-C., Lemster, S., Stefek, A., Ruhland, F., Hofmann, M., Schuster, J., Simon, W., Kronawitter, U., Clemens, M., Janni, W., Latos, K., Bauer, W., Roßmann, A., Bauer, L., Lampe, D., Heyl, V., Hoffmann, G., Lorenz-Salehi, F., Hackmann, J., and Schlag, R.

Published
2014
Full Text
View/download PDF

6. Intelligente vakuum-assistierte Biopsie zur Identifikation von Brustkrebspatientinnen mit pathologischer Komplettremmission (ypT0, ypN0) nach neoadjuvanter Systemtherapie für den Verzicht einer Operation von Brust und Axilla

Author

Pfob, A., additional, Sidey-Gibbons, C., additional, Rauch, G., additional, Thomas, B., additional, Schäfgen, B., additional, Kuemmel, S., additional, Reimer, T., additional, Hahn, M., additional, Thill, M., additional, Blohmer, J.-U., additional, Hackmann, J., additional, Malter, W., additional, Bekes, I., additional, Friedrichs, K., additional, Wojcinski, S., additional, Joos, S., additional, Paepke, S., additional, Degenhardt, T., additional, Rom, J., additional, Rody, A., additional, van Mackelenbergh, M., additional, Banys-Paluchowski, M., additional, Große, R., additional, Reinisch, M., additional, Karsten, M., additional, Golatta, M., additional, and Heil, J., additional

Published
2022
Full Text
View/download PDF

9. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Author

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., Walter-Kirst, R., Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M., and Walter-Kirst, R.

Abstract

PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULT Of the 3,198 registered patients, 348 (RS <= 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v60.8%; pNO, 58.2% v59.5%; pT1, 57.6% v52.3%; HR positive, 81.4% v82.2%; RS greater than 25 [in H.R-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v89.9% [95% CI, 88.1% to 91.8%]; OS, 94.5% [95% CI, 93.1% to 95.9%] v94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), de

Published
2019

10. Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer-GBG69

Author

Schneeweiss, A., Jackisch, C., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kummel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J. U., Gerber, B., Furlanetto, J., von Minckwitz, G., Nekljudova, V., Loibl, S., and Untch, M.

Subjects
Medizin
Published
2018

11. Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Prat, A, additional, Christgen, M, additional, Feuerhake, F, additional, Garke, M, additional, Grischke, E-M, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Kuemmel, S, additional, Pelz, E, additional, Gebauer, D, additional, Paré, L, additional, Kates, R, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2019
Full Text
View/download PDF

12. Abstract P2-08-10: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials

Author

Villegas, SL, primary, Lederer, B, additional, Untch, M, additional, Holms, F, additional, Ulmer, H-U, additional, Diebold, K, additional, Fasching, PA, additional, Weber, K, additional, Schmitt, WD, additional, Tesch, H, additional, Rezai, M, additional, Marmé, F, additional, Sinn, B, additional, Hackmann, J, additional, Schneeweiss, A, additional, Tannapfel, A, additional, Nekljudova, V, additional, Denkert, C, additional, and Loibl, S, additional

Published
2019
Full Text
View/download PDF

13. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Author

Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G., Loibl, S., Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G., and Loibl, S.

Published
2018

14. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer : a subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S, Jackisch, C, Schneeweiss, A, Schmatloch, S, Aktas, B, Denkert, C, Wiebringhaus, H, Kümmel, S, Warm, M, Paepke, S, Just, M, Hanusch, C, Hackmann, J, Blohmer, J-U, Clemens, M, Costa, S Dan, Gerber, B, Engels, K, Nekljudova, V, von Minckwitz, G, Untch, M, and investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie--Breast (AGO-B) study groups.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Paclitaxel, Receptor, ErbB-2, medicine.medical_treatment, Medizin, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, Albumins, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Anthracyclines, skin and connective tissue diseases, neoplasms, Neoadjuvant therapy, Aged, Epirubicin, Neoplasm Staging, Chemotherapy, business.industry, Cancer, Hematology, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Pertuzumab, Fluorouracil, business, medicine.drug
Abstract

The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic complete response (pCR) rate achieved with a sequential neoadjuvant chemotherapy regimen of paclitaxel, epirubicin, and cyclophosphamide for high-risk primary breast cancer. Recent trials demonstrated that in HER2+ breast cancer pCR can be increased by using pertuzumab in addition to trastuzumab and chemotherapy. The present analysis focuses on efficacy and safety data from the subset of patients with HER2+ tumors from the GeparSepto trial (n = 396) in comparison to the HER2- cohort.Patients with histologically confirmed breast cancer (n = 1206) received four cycles of weekly paclitaxel [either solvent-based (Pac) or nab-paclitaxel (nab-Pac), according to randomization] followed by 4 cycles of epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 q3w, with concurrent trastuzumab and pertuzumab q3w for those with HER2+ tumors. The primary endpoint was pCR defined as ypT0 ypN0.Higher rates of pCR were achieved in HER2+ than in HER2- tumors (57.8% versus 22.0%, P 0.0001), with the highest rate in the HER2+/HR- cohort (71.0%; 66.7% Pac, 74.6% nab-Pac). In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). Grade ≥3 toxic effects were significantly more common in HER2+ than in HER2- patients, with grade 3-4 diarrhea in 7.6% versus 0.9% (P 0.001) and febrile neutropenia in 6.3% versus 3.3% (P = 0.023) of patients. Left ventricular ejection fraction decreases from baseline were uncommon, with 2.0% versus 0.4% of patients showing decreases to 50% along with a ≥10% decrease from baseline.In HER2+ early breast cancer, a dual HER2-targeted combination of pertuzumab and trastuzumab, together with taxane-epirubicin-cyclophosphamide neoadjuvant chemotherapy, achieved high rates of pCR.

Published
2017

15. Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Author

Untch, M., primary, Jackisch, C., additional, Schneeweiss, A., additional, Schmatloch, S., additional, Aktas, B., additional, Denkert, C., additional, Schem, C., additional, Wiebringhaus, H., additional, Kümmel, S., additional, Rhiem, K., additional, Warm, M., additional, Fasching, P.A., additional, Just, M., additional, Hanusch, C., additional, Hackmann, J., additional, Blohmer, J.-U., additional, Furlanetto, J., additional, Nekljudova, V., additional, von Minckwitz, G., additional, and Loibl, S., additional

Published
2018
Full Text
View/download PDF

16. Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Author

Gluz, O., primary, Nitz, U., additional, Liedtke, C., additional, Christgen, M., additional, Grischke, E.-M., additional, Forstbauer, H., additional, Braun, M., additional, Warm, M., additional, Hackmann, J., additional, Uleer, C., additional, Aktas, B., additional, Schumacher, C., additional, Lindner, C., additional, Kümmel, S., additional, Kates, R.E., additional, Potenberg, J., additional, Staib, P., additional, Wuerstlein, R., additional, Kreipe, H.H., additional, and Harbeck, N., additional

Published
2018
Full Text
View/download PDF

17. Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Author

Schneeweiss, A, primary, Jackisch, C, additional, Schmatloch, S, additional, Aktas, B, additional, Denkert, C, additional, Schem, C, additional, Wiebringhaus, H, additional, Kümmel, S, additional, Rhiem, K, additional, Warm, M, additional, Fasching, PA, additional, Just, M, additional, Hanusch, C, additional, Hackmann, J, additional, Blohmer, JU, additional, Gerber, B, additional, Furlanetto, J, additional, von Minckwitz, G, additional, Nekljudova, V, additional, Loibl, S, additional, and Untch, M, additional

Published
2018
Full Text
View/download PDF

18. nab-paclitaxel at a dose of 125 mg/m(2) weekly is more efficacious but less toxic than at 150 mg/m(2) : Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Author

Untch, M., von Minckwitz, G., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kuemmel, S., Hilfrich, J., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J. Uwe, Clemens, M., Costa, S. Dan, Gerber, B., Nekljudova, V., and Loibl, S.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2016

19. Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer : WSG-ADAPT TN randomized phase II trial

Author

Potenberg, J, Liedtke, C, Grischke, EM, Warm, M, Staib, P, Harbeck, N, Kreipe, HH, Wuerstlein, R, Kuemmel, S, Lindner, C, Kates, RE, Pelz, E, Uleer, C, Nitz, U, Aktas, B, Forstbauer, H, Schumacher, C, Gluz, O, Braun, M, Kohls, A, Hackmann, J, Clemens, M, Christgen, M, Bangemann, N, and Sotlar, K

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2016

20. Abstract P4-21-06: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial

Author

Loibl, S, primary, Jackisch, J, additional, Schneeweiss, A, additional, Schmatloch, S, additional, Aktas, B, additional, Denkert, C, additional, Schem, C, additional, Wiebringhaus, H, additional, Kuemmel, S, additional, Luebbe, K, additional, Warm, M, additional, Just, M, additional, Hanusch, C, additional, Hackmann, J, additional, Blohmer, J-U, additional, Clemens, M, additional, Engels, K, additional, Nekljudova, V, additional, von Minckwitz, G, additional, and Untch, M, additional

Published
2017
Full Text
View/download PDF

21. Abstract P5-16-03: Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Author

Furlanetto, J, primary, von Minckwitz, G, additional, Jackisch, C, additional, Schneeweiss, A, additional, Aktas, B, additional, Denkert, C, additional, Wiebringhaus, H, additional, Kuemmel, S, additional, Warm, M, additional, Paepke, S, additional, Just, M, additional, Hanusch, C, additional, Hackmann, J, additional, Blohmer, J-U, additional, Clemens, M, additional, Costa, SD, additional, Gerber, B, additional, Nekljudova, V, additional, Untch, M, additional, and Loibl, S, additional

Published
2017
Full Text
View/download PDF

22. Ion temperature measurements in a tokamak by collective Thomson scattering.

Author

Siegrist, M. R., Behn, R., Dicken, D., Duval, B. P., Hackmann, J., Joye, B., Lister, J., Nieswand, C., Pochelon, A., Soumagne, G., and Yuan, D. C.

Subjects
THOMSON scattering, TOKAMAKS
Abstract

Focuses on the use of collective Thomson scattering to provide local ion temperature measurements of the plasma in the tokamak chauffage Alfvén tokamak. Description of the apparatus used in the experiment;Technique used to measure system noise temperature of the heterodyne detection system.

Published
1991
Full Text
View/download PDF

24. Vergleich der 12-wöchigen neoadjuvanten Chemotherapie mit Nab-Paclitaxel mit Gemcitabine vs. Carboplatin bei Patientinnen mit triple-negativem Mammakarzinom: ADAPT-TN randomiiserte Phase II Studie

Author

Grischke, EM, primary, Gluz, O, additional, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kates, R, additional, Würstlein, R, additional, Kreipe, H, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

25. Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Sotlar, K, additional, Grischke, EM, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kohls, A, additional, Pelz, E, additional, Kates, RE, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

26. Abstract P1-14-11: nab-paclitaxel at a dose of 125 mg/m2 weekly is more efficacious but less toxic than at 150 mg/m2. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Author

von Minckwitz, G, primary, Untch, M, additional, Jakisch, C, additional, Schneeweiss, A, additional, Conrad, B, additional, Aktas, B, additional, Denkert, C, additional, Eidtmann, H, additional, Weibringhaus, H, additional, Kümmel, S, additional, Hilfrich, J, additional, Warm, M, additional, Paepke, S, additional, Just, M, additional, Hanusch, C, additional, Hackmann, J, additional, Blohmer, J-U, additional, Clemens, M, additional, Costa, SD, additional, Gerber, B, additional, Nekljudova, V, additional, and Loibl, S, additional

Published
2016
Full Text
View/download PDF

27. Abstract P1-13-01: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Author

Gluz, O, primary, Nitz, U, additional, Liedtke, C, additional, Christgen, M, additional, Sotlar, K, additional, Grischke, EM, additional, Forstbauer, H, additional, Braun, M, additional, Warm, M, additional, Hackmann, J, additional, Uleer, C, additional, Aktas, B, additional, Schumacher, C, additional, Bangemann, N, additional, Lindner, C, additional, Kuemmel, S, additional, Clemens, M, additional, Potenberg, J, additional, Staib, P, additional, Kohls, A, additional, Pelz, E, additional, Kates, RE, additional, Wuerstlein, R, additional, Kreipe, HH, additional, and Harbeck, N, additional

Published
2016
Full Text
View/download PDF

29. LBA13 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Author

Gluz, O., Nitz, U., Liedtke, C., Christgen, M., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Lindner, C., Kümmel, S., Kates, R.E., Potenberg, J., Staib, P., Wuerstlein, R., Kreipe, H.H., and Harbeck, N.

Published
2018
Full Text
View/download PDF

30. 188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Author

Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kümmel, S., Rhiem, K., Warm, M., Fasching, P.A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G., and Loibl, S.

Published
2018
Full Text
View/download PDF

35. Hormonrezeptor-(HR)-Expression im Vergleich von Lokal- und Zentralpathologie sowie RT-PCR-basierte Analyse (Recurrence Score, RS, Oncotype DX): Ergebnisse aus der Plan B Studie

Author

Schumann, R von, primary, Gluz, O, additional, Nitz, U, additional, Clemens, M, additional, Lübbe, K, additional, Aktas, B, additional, Just, M, additional, Noesselt, T, additional, Henschen, S, additional, Hackmann, J, additional, Lorenz-Salehi, F, additional, Freese, K, additional, Svedmann, C, additional, Kates, R, additional, Kreipe, H, additional, Harbeck, N, additional, and Liedtke, C, additional

Published
2015
Full Text
View/download PDF

41. PD07-06: Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial.

Author

Nitz, U, primary, Gluz, O, additional, Oberhoff, C, additional, Reimer, T, additional, Schumacher, C, additional, Hackmann, J, additional, Warm, M, additional, Uleer, C, additional, Runde, V, additional, Kuemmel, S, additional, Zuna, I, additional, and Harbeck, N, additional

Published
2011
Full Text
View/download PDF

43. 5201 POSTER The EXpand Study – Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone

Author

Hellrieqel, M., primary, Mueller, M., additional, Reimer, T., additional, Baerens, D.T., additional, von der Assen, A., additional, Hackmann, J., additional, Schmidt, K., additional, Baier-Ebert, M., additional, Spall, T., additional, and Emons, G., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results